homepage-top-section

Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn. Under the terms

Philip Morris International (PMI) has agreed to acquire British pharmaceutical firm Vectura Group for about $1.183bn (£852m) to expand its product pipeline development capabilities in inhaled therapeutics. The

Verge Genomics has announced a three-year partnership with Eli Lilly and Company to discover and develop novel therapies for amyotrophic lateral sclerosis (ALS), a motor neuron disease. As

Altesa Biosciences has signed an exclusive worldwide license agreement with biotechnology firm Vaxart for the development and commercialisation of the latter’s patented formulation of the capsid-binding Vapendavir antiviral.

The European Commission has cleared AstraZeneca’s proposed acquisition of Alexion Pharmaceuticals for $39bn. This marks an ‘important step’ towards the completion of the acquisition, which was first announced

The Russian Direct Investment Fund (RDIF) has announced the production of a test batch of the Russian Covid-19 vaccine, Sputnik V, in Mexico. With this production, Mexico has

GlaxoSmithKline (GSK) and Alector have partnered to co-develop and commercialise two clinical stage monoclonal antibodies for neurodegenerative diseases. Under the deal, the companies will co-develop AL001 and AL101

Philip Morris International has signed an agreement to acquire Fertin Pharma from private equity firm EQT for approximately $812.8m (DKK5.1bn). Denmark-based Fertin Pharma is a specialist contract development

Spanish healthcare company Grifols announced that Singapore’s wealth fund GIC agreed to invest about $1bn in Grifols’ wholly owned US subsidiary Biomat USA. As part of the definitive